Eruptive melanocytic nevi associated with ponatinib
Sign Up to like & getrecommendations! Published in 2018 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2018.07.010
Abstract: Ponatinib (ICLUSIG, Takeda; Osaka, Japan) is an oral third-generation tyrosine kinase inhibitor (TKI) approved by US Food and Drug Administration in 2012 used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic… read more here.
Keywords: associated ponatinib; nevi associated; melanocytic nevi; eruptive melanocytic ... See more keywords